Literature DB >> 15276105

Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.

Deepak P Vivekananthan1, Deepak L Bhatt, Derek P Chew, Frank J Zidar, Albert W Chan, David J Moliterno, Stephen G Ellis, Eric J Topol.   

Abstract

This study sought to determine the effect of clopidogrel pretreatment on the increase in C-reactive protein (CRP) after percutaneous coronary intervention. Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15276105     DOI： 10.1016/j.amjcard.2004.04.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  16 in total

1.  Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.

Authors:  Steven R Steinhubl; David J Schneider; Peter B Berger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2007-11-01       Impact factor: 2.300

Review 2.  Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists.

Authors:  Srinivas Iyengar; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2008-04-09       Impact factor: 2.300

Review 3.  Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.

Authors:  Sven Nylander; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2016-02-24       Impact factor: 8.739

4.  Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease.

Authors:  Ronnie Ramadan; Saurabh S Dhawan; Hamid Syed; F Khan Pohlel; Jose N G Binongo; Ziyad B Ghazzal; Arshed A Quyyumi
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

5.  Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.

Authors:  Preethi Mani; Rishi Puri; Gregory G Schwartz; Steven E Nissen; Mingyuan Shao; John J P Kastelein; Venu Menon; A Michael Lincoff; Stephen J Nicholls
Journal:  JAMA Cardiol       Date:  2019-04-01       Impact factor: 14.676

Review 6.  Clopidogrel: a review of its use in the prevention of thrombosis.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.

Authors:  James T Willerson; Greg Cable; Edward T H Yeh
Journal:  Tex Heart Inst J       Date:  2009

8.  Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.

Authors:  Xiaowen Tu; Xiangmei Chen; Yuansheng Xie; Suozhu Shi; Jianzhong Wang; Yunshuang Chen; Jianjun Li
Journal:  J Am Soc Nephrol       Date:  2007-11-28       Impact factor: 10.121

9.  Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.

Authors:  Mehmet Akbulut; Makbule Kutlu; Yilmaz Ozbay; Veli Polat; Mehmet Nail Bilen; Adil Baydas; Yakup Altas
Journal:  Mediators Inflamm       Date:  2009-04-12       Impact factor: 4.711

10.  Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.

Authors:  Joanna J Wykrzykowska; Ascan Warnholtz; Peter de Jaeger; Nick Curzen; Keith G Oldroyd; Jean Philippe Collet; Jurrien M Ten Berg; Tessa Rademaker; Dick Goedhart; Jurgen Lissens; Peter-Paul Kint; Patrick W Serruys
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.